Human PLA2R1/CLEC13C/PLA2-R ORF/cDNA clone-Adenovirus particle (NM_007366.5)

Cat. No.: vGMAD001510

Pre-made Human PLA2R1/CLEC13C/PLA2-R Adenovirus for PLA2R1 overexpression in-vitro and in-vivo. The PLA2R1 adenoviral vector excels as a vehicle for transient gene transfection in both stable cell lines and primary cells, including DC cells, macrophages, cardiomyocytes, hepatocytes, and neurons. The purified PLA2R1-encoding adenovirus also stands out as a quintessential tool for in vivo studies and vaccine research initiatives.

At GM Vector Core (GMVC), we provide bespoke adenovirus development and manufacture various grades of adenoviruses utilizing cutting-edge techniques. Dive deeper into our offerings.

Target products collection

Go to PLA2R1/PLA2R/PLA2R1/CLEC13C products collection>>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdf MSDS
pdf Datasheet

Product information

Catalog No. Product Name Adenovirus Grade Adenovirus quantity
vGMAD001510 Human PLA2R1 Adenovirus particle Research Grade-In vitro 1E+10PFU (1E+10pfu/ml×1ml)
5E+10PFU (1E+10pfu/ml×5ml)
1E+11PFU (1E+10pfu/ml×10ml)
Research Grade-In vivo 1E+11PFU (1E+11pfu/ml×1ml)
GMP-like Grade inquiry
GMP Grade inquiry


Product Description

Catalog ID vGMAD001510
Gene Name PLA2R1
Accession Number NM_007366.5
Gene ID 22925
Species Human
Product Type Adenovirus particle (overexpression)
Insert Length 4392 bp
Gene Alias CLEC13C,PLA2-R,PLA2G1R,PLA2IR,PLA2R
Fluorescent Reporter EGFP
Mammalian Cell Selection Null
Fusion Tag 3xflag (C-Terminal)
Promoter EF1
Resistance Kanamycin
ORF Nucleotide Sequence ATGCTGCTGTCGCCGTCGCTGCTGCTGCTGCTGCTGCTGGGGGCGCCGCGGGGCTGCGCCGAGGGTGTGGCGGCGGCGCTTACCCCCGAGCGGCTCCTGGAGTGGCAGGATAAAGGAATATTTGTTATCCAAAGTGAGAGTCTCAAGAAATGCATTCAAGCAGGTAAATCGGTTCTGACCCTGGAGAACTGCAAGCAAGCAAACAAGCACATGCTGTGGAAATGGGTTTCAAACCATGGCCTCTTTAACATAGGAGGCAGTGGTTGCCTGGGCCTGAATTTCTCCGCCCCAGAGCAGCCATTAAGCTTATATGAATGTGACTCCACCCTCGTTTCCTTACGGTGGCGCTGTAACAGGAAGATGATCACAGGCCCGCTGCAGTACTCTGTCCAGGTGGCGCATGACAACACAGTGGTGGCCTCACGGAAGTATATTCATAAGTGGATTTCTTATGGGTCAGGTGGTGGAGACATTTGTGAATATCTACACAAAGATTTGCATACAATCAAAGGGAACACCCACGGGATGCCGTGTATGTTTCCCTTCCAGTATAACCATCAGTGGCATCATGAATGTACCCGTGAAGGTCGGGAAGATGACTTACTGTGGTGTGCCACGACAAGCCGTTATGAAAGAGATGAAAAGTGGGGATTTTGCCCTGATCCCACCTCTGCAGAAGTAGGTTGTGATACTATTTGGGAGAAGGACCTCAATTCACACATTTGCTACCAGTTCAACCTGCTTTCATCTCTCTCTTGGAGTGAGGCACATTCTTCATGCCAGATGCAAGGAGGTACGCTGTTAAGTATTACAGATGAAACTGAAGAAAATTTCATAAGGGAGCACATGAGCAGTAAAACAGTGGAGGTGTGGATGGGCCTCAATCAGCTGGATGAACACGCTGGCTGGCAGTGGTCTGATGGAACGCCGCTCAACTATCTGAATTGGAGCCCAGAGGTAAATTTTGAGCCATTTGTTGAAGATCACTGTGGAACATTTAGTTCATTTATGCCAAGTGCCTGGAGGAGTCGGGATTGTGAGTCCACCTTGCCATATATATGTAAAAAATATCTAAACCACATTGATCATGAAATAGTTGAAAAAGATGCGTGGAAATATTATGCTACCCACTGTGAGCCTGGCTGGAATCCCTACAATCGTAATTGCTACAAACTTCAGAAAGAAGAAAAGACCTGGCATGAGGCTCTGCGTTCTTGTCAGGCTGATAACAGTGCATTAATAGACATAACCTCATTAGCAGAGGTGGAGTTTCTTGTAACCCTCCTTGGAGATGAAAATGCATCAGAAACATGGATTGGTTTGAGCAGCAATAAAATTCCAGTTTCCTTTGAATGGTCTAATGACTCTTCAGTCATCTTTACTAATTGGCACACACTTGAGCCCCACATTTTTCCAAATAGAAGCCAGCTGTGTGTCTCAGCAGAGCAGTCTGAGGGACACTGGAAAGTCAAAAATTGTGAAGAAAGACTTTTTTACATTTGTAAAAAAGCAGGCCATGTCCTCTCTGATGCTGAATCAGGATGTCAAGAGGGATGGGAGAGACATGGTGGATTCTGTTACAAAATTGACACAGTCCTTCGAAGCTTTGACCAAGCTTCCAGCGGTTATTACTGTCCTCCTGCACTTGTAACCATTACAAACAGGTTTGAACAGGCTTTTATTACCAGTTTGATCAGTAGTGTGGTAAAAATGAAGGACAGTTATTTTTGGATAGCTCTTCAGGACCAAAATGATACGGGAGAATACACTTGGAAGCCAGTAGGGCAGAAACCCGAGCCGGTGCAGTACACACACTGGAACACACACCAGCCGCGCTACAGTGGTGGCTGTGTTGCCATGCGAGGAAGGCATCCACTTGGTCGCTGGGAAGTGAAGCACTGTCGGCACTTTAAGGCAATGTCCTTGTGCAAGCAGCCAGTTGAAAATCAGGAAAAAGCAGAGTATGAAGAGAGATGGCCCTTTCACCCCTGCTATTTGGACTGGGAGTCAGAGCCTGGTCTGGCCAGTTGCTTCAAGGTATTTCATAGTGAAAAAGTTCTGATGAAAAGAACATGGAGAGAAGCTGAAGCATTTTGCGAAGAATTTGGAGCTCATCTTGCAAGCTTTGCCCATATTGAGGAAGAGAATTTTGTGAATGAGCTCTTACATTCAAAATTTAATTGGACAGAAGAAAGGCAGTTCTGGATTGGATTTAATAAAAGAAACCCACTGAATGCCGGCTCATGGGAGTGGTCTGATAGAACTCCTGTTGTCTCTTCGTTTTTAGACAACACTTATTTTGGAGAAGATGCAAGAAACTGTGCTGTTTATAAGGCAAACAAAACATTGCTGCCCTTACACTGTGGTTCCAAACGTGAATGGATATGCAAAATCCCAAGAGATGTGAAACCCAAGATTCCGTTCTGGTACCAGTACGATGTACCCTGGCTCTTTTATCAGGATGCAGAATACCTTTTTCATACCTTTGCCTCAGAATGGTTGAACTTTGAGTTTGTCTGTAGCTGGCTGCACAGTGATCTTCTCACAATTCATTCTGCACATGAGCAAGAATTCATCCACAGCAAAATAAAAGCGCTATCAAAGTATGGTGCAAGTTGGTGGATTGGACTTCAAGAAGAAAGAGCCAATGATGAATTTCGCTGGAGAGATGGAACACCAGTGATATACCAGAACTGGGACACAGGAAGAGAAAGAACTGTGAATAATCAGAGCCAGAGATGTGGCTTTATTTCTTCTATAACAGGACTCTGGGGTAGTGAAGAGTGTTCAGTTTCTATGCCTAGTATCTGTAAGCGAAAAAAGGTTTGGCTCATAGAGAAAAAGAAAGATACACCAAAACAACATGGAACGTGTCCCAAAGGATGGCTATATTTTAACTATAAGTGCCTTCTGCTGAATATCCCCAAAGACCCAAGCAGTTGGAAGAACTGGACGCATGCTCAACATTTCTGTGCTGAAGAAGGGGGGACCCTGGTCGCCATTGAAAGTGAGGTGGAGCAAGCTTTCATTACTATGAATCTTTTTGGCCAGACCACCAGTGTGTGGATAGGTTTACAAAATGATGATTATGAAACATGGCTAAATGGAAAGCCTGTGGTATATTCTAACTGGTCTCCATTTGATATAATAAATATTCCAAGTCACAATACCACTGAAGTTCAGAAACACATTCCTCTCTGTGCCTTACTCTCAAGTAATCCTAATTTTCATTTCACTGGAAAATGGTATTTTGAAGACTGTGGAAAGGAAGGCTATGGGTTTGTTTGTGAAAAAATGCAAGATACTTCTGGACACGGTGTAAATACATCTGATATGTATCCAATGCCCAATACCTTAGAATATGGAAACAGAACTTACAAAATAATTAATGCAAATATGACTTGGTATGCAGCAATAAAAACCTGCCTGATGCACAAAGCACAACTGGTCAGCATCACAGACCAGTATCACCAGTCCTTCCTCACTGTTGTCCTCAACCGGCTAGGATATGCCCACTGGATTGGACTGTTCACCACAGATAATGGTCTTAATTTTGACTGGTCTGATGGCACCAAATCTTCTTTCACTTTTTGGAAAGATGAGGAGTCCTCCCTCCTTGGTGACTGCGTTTTTGCCGACAGCAACGGACGCTGGCATAGCACAGCCTGCGAGTCATTTCTGCAAGGTGCCATTTGTCATGTGCCACCTGAAACAAGACAATCTGAACACCCAGAGTTGTGCTCAGAAACATCTATTCCCTGGATAAAATTTAAAAGTAATTGCTACAGTTTTTCTACAGTCCTAGACAGTATGAGTTTTGAGGCTGCTCATGAATTTTGCAAAAAGGAAGGTTCTAATCTTTTAACAATCAAGGATGAGGCTGAAAATGCATTTCTCCTAGAAGAGCTGTTTGCTTTTGGTTCTTCTGTCCAGATGGTTTGGTTGAATGCTCAATTTGATGGTAACAATGAAACCATAAAGTGGTTTGATGGAACTCCCACAGACCAGTCAAACTGGGGCATTCGGAAGCCAGACACAGACTACTTCAAGCCCCATCATTGTGTTGCCTTGAGGATCCCTGAAGGATTATGGCAGCTATCCCCGTGTCAAGAAAAAAAAGGCTTTATATGTAAAATGGAGGCAGATATTCACACTGCAGAGGCGCTGCCAGAAAAAGGACCAAGTCACAGCATCATTCCTCTTGCGGTTGTACTGACACTGATAGTCATTGTGGCCATTTGCACACTTTCCTTCTGCATATACAAGCATAACGGTGGCTTCTTCAGGAGACTTGCAGGGTTTCGGAATCCTTACTATCCTGCAACCAACTTTAGTACAGTATATTTAGAAGAAAATATTCTCATTTCTGATCTTGAGAAGAGTGACCAATAA
ORF Protein Sequence MLLSPSLLLLLLLGAPRGCAEGVAAALTPERLLEWQDKGIFVIQSESLKKCIQAGKSVLTLENCKQANKHMLWKWVSNHGLFNIGGSGCLGLNFSAPEQPLSLYECDSTLVSLRWRCNRKMITGPLQYSVQVAHDNTVVASRKYIHKWISYGSGGGDICEYLHKDLHTIKGNTHGMPCMFPFQYNHQWHHECTREGREDDLLWCATTSRYERDEKWGFCPDPTSAEVGCDTIWEKDLNSHICYQFNLLSSLSWSEAHSSCQMQGGTLLSITDETEENFIREHMSSKTVEVWMGLNQLDEHAGWQWSDGTPLNYLNWSPEVNFEPFVEDHCGTFSSFMPSAWRSRDCESTLPYICKKYLNHIDHEIVEKDAWKYYATHCEPGWNPYNRNCYKLQKEEKTWHEALRSCQADNSALIDITSLAEVEFLVTLLGDENASETWIGLSSNKIPVSFEWSNDSSVIFTNWHTLEPHIFPNRSQLCVSAEQSEGHWKVKNCEERLFYICKKAGHVLSDAESGCQEGWERHGGFCYKIDTVLRSFDQASSGYYCPPALVTITNRFEQAFITSLISSVVKMKDSYFWIALQDQNDTGEYTWKPVGQKPEPVQYTHWNTHQPRYSGGCVAMRGRHPLGRWEVKHCRHFKAMSLCKQPVENQEKAEYEERWPFHPCYLDWESEPGLASCFKVFHSEKVLMKRTWREAEAFCEEFGAHLASFAHIEEENFVNELLHSKFNWTEERQFWIGFNKRNPLNAGSWEWSDRTPVVSSFLDNTYFGEDARNCAVYKANKTLLPLHCGSKREWICKIPRDVKPKIPFWYQYDVPWLFYQDAEYLFHTFASEWLNFEFVCSWLHSDLLTIHSAHEQEFIHSKIKALSKYGASWWIGLQEERANDEFRWRDGTPVIYQNWDTGRERTVNNQSQRCGFISSITGLWGSEECSVSMPSICKRKKVWLIEKKKDTPKQHGTCPKGWLYFNYKCLLLNIPKDPSSWKNWTHAQHFCAEEGGTLVAIESEVEQAFITMNLFGQTTSVWIGLQNDDYETWLNGKPVVYSNWSPFDIINIPSHNTTEVQKHIPLCALLSSNPNFHFTGKWYFEDCGKEGYGFVCEKMQDTSGHGVNTSDMYPMPNTLEYGNRTYKIINANMTWYAAIKTCLMHKAQLVSITDQYHQSFLTVVLNRLGYAHWIGLFTTDNGLNFDWSDGTKSSFTFWKDEESSLLGDCVFADSNGRWHSTACESFLQGAICHVPPETRQSEHPELCSETSIPWIKFKSNCYSFSTVLDSMSFEAAHEFCKKEGSNLLTIKDEAENAFLLEELFAFGSSVQMVWLNAQFDGNNETIKWFDGTPTDQSNWGIRKPDTDYFKPHHCVALRIPEGLWQLSPCQEKKGFICKMEADIHTAEALPEKGPSHSIIPLAVVLTLIVIVAICTLSFCIYKHNGGFFRRLAGFRNPYYPATNFSTVYLEENILISDLEKSDQ

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    Category Cat No. Products Name
    Target Antibody GM-Tg-g-T46702-Ab Anti-PLA2R/ PLA2R1/ CLEC13C monoclonal antibody
    Target Antigen GM-Tg-g-T46702-Ag PLA2R/PLA2R1 VLP (virus-like particle)
    ORF Viral Vector pGMAD001510 Human PLA2R1 Adenovirus plasmid
    ORF Viral Vector vGMAD001510 Human PLA2R1 Adenovirus particle


    Target information

    Target ID GM-T46702
    Target Name PLA2R1/PLA2R
    Gene Group Identifier
    （Target Gene ID in Homo species)         		22925
    Gene ID 100060317 (Equus caballus), 101096335 (Felis catus), 18779 (Mus musculus), 22925 (Homo sapiens)
    295631 (Rattus norvegicus), 317777 (Bos taurus), 488367 (Canis lupus familiaris), 700191 (Macaca mulatta)
    Gene Symbols & Synonyms PLA2R1,Pla2r1,Pla2r,Pla2-r,Pla2g1br,PLA2R,PLA2-R,PLA2IR,CLEC13C,PLA2G1R
    Target Alternative Names 180 kDa secretory phospholipase A2 receptor,C-type lectin domain family 13 member C,CLEC13C,M-type receptor,PLA2-R,PLA2G1R,PLA2IR,PLA2R,PLA2R1,Pla2-r,Pla2g1br,Pla2r,Pla2r1,Secretory phospholipase A2 receptor
    Uniprot Accession P49259,Q13018,Q62028
    Additional SwissProt Accessions: Q62028,Q13018,P49259
    Uniprot Entry Name
    Protein Sub-location Transmembrane Protein
    Category Therapeutics Target
    Disease
    Disease from KEGG Phagosome, Tuberculosis
    Gene Ensembl ENSECAG00000023815, ENSMUSG00000054580, ENSG00000153246, ENSBTAG00000032515, ENSCAFG00845028931, ENSMMUG00000051450
    Target Classification


    About GMVC

    GDU

    GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.